The development of airway hyperreactivity in T-bet-deficient mice requires CD1d-restricted NKT cells.
T-bet(-/-) mice have been shown to have a profound deficiency in the ability to generate invariant NKT (iNKT) cells in the periphery due to a halt in terminal maturation, but despite this deficiency, T-bet(-/-) mice develop spontaneous airway hyperreactivity (AHR) and airway inflammation. Because in some situations the development of AHR requires the presence of iNKT cells, we sought to more clearly understand how AHR develops in T-bet(-/-) mice by examining T-bet(-/-) mice in several distinct mouse models of asthma, including spontaneous, OVA-induced and alpha-galactosylceramide (alpha-GalCer)-induced AHR. Surprisingly, we found that administration of alpha-GalCer, which very specifically activates iNKT cells, greatly increased the AHR response in the T-bet(-/-) mice. Moreover, in T-bet(-/-) mice, spontaneous AHR as well as AHR induced with OVA or alpha-GalCer were all eliminated by blocking CD1d, the restricting element of iNKT cells, using an anti-CD1d-blocking mAb. Although the number of the iNKT cells in T-bet(-/-) mice was reduced compared with that in wild-type mice, the remaining iNKT cells produced primarily IL-4 and IL-13, and only minimal amounts of IFN-gamma. We conclude therefore that the AHR that develops in T-bet(-/-) mice is dependent on the presence of iNKT cells, and that whereas T-bet(-/-) have reduced numbers of iNKT cells, these are sufficient for the development of AHR.
Kim
Hye Young
HY
Division of Immunology and Allergy, Children's Hospital Boston, Harvard Medical School, Boston, MA 02115, USA.
Pichavant
Muriel
M
Matangkasombut
Ponpan
P
Koh
Youngil I
YI
Savage
Paul B
PB
DeKruyff
Rosemarie H
RH
Umetsu
Dale T
DT
D000818:Animals; D019138:Antibodies, Blocking / Q000378:metabolism; D055610:Antigens, CD1d / Q000276:immunology* / Q000378:metabolism; D016535:Bronchial Hyperreactivity / Q000235:genetics / Q000276:immunology* / Q000473:pathology; D004195:Disease Models, Animal; D018984:Epitopes, T-Lymphocyte / Q000276:immunology / Q000378:metabolism; D005699:Galactosylceramides / Q000276:immunology / Q000633:toxicity; D008231:Lymphopenia / Q000235:genetics / Q000276:immunology / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D018345:Mice, Knockout; D008822:Mice, Transgenic; D055611:Natural Killer T-Cells / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D010047:Ovalbumin / Q000276:immunology / Q000633:toxicity; D020825:T-Box Domain Proteins / Q000172:deficiency* / Q000235:genetics* / Q000502:physiology; D000098815:T-bet Transcription Factor
D019138:Antibodies, Blocking; D055610:Antigens, CD1d; D018984:Epitopes, T-Lymphocyte; D005699:Galactosylceramides; D020825:T-Box Domain Proteins; D000098815:T-bet Transcription Factor; C493154:alpha-galactosylceramide; D010047:Ovalbumin